Nonami Atsushi, Takenaka Katsuto, Kamezaki Kenjiro, Miyamoto Toshihiro, Harada Naoki, Nagafuji Koji, Teshima Takanori, Harada Mine
First Department of Internal Medicine, Kyushu University, Fukuoka, Japan.
Int J Hematol. 2007 Apr;85(3):264-6. doi: 10.1532/IJH97.06197.
Primary cardiac lymphoma (PCL) is defined as lymphoma involving only the heart and/or pericardium, or with an intrapericardial location of the main tumor mass. It is an extremely rare type of lymphoma and has a poor prognosis because of diagnostic delay and the disease site. PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. The median survival time has been reported to be 7 months. We present the case of a 55-year-old woman who presented with chest oppression and dyspnea on effort. Following a close examination, PCL with a high International Prognostic Index was diagnosed. She received 6 courses of R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and achieved complete remission. The patient then underwent a consolidation therapy consisting of high-dose chemotherapy including rituximab, followed by autologous peripheral blood stem cell transplantation. There were no complications, such as pulmonary embolism, fatal arrhythmia, or acute heart failure, throughout chemotherapy. Our experience indicates that this therapy is safe and effective and can improve the outcome of high-risk PCL.
原发性心脏淋巴瘤（PCL）定义为仅累及心脏和/或心包，或主要肿瘤位于心包内的淋巴瘤。它是一种极其罕见的淋巴瘤类型，由于诊断延迟和疾病部位的原因，预后较差。PCL的组织学特征主要为弥漫性大B细胞淋巴瘤。据报道，中位生存时间为7个月。我们报告一例55岁女性患者，她出现胸部压迫感和劳力性呼吸困难。经过仔细检查，诊断为国际预后指数较高的PCL。她接受了6个疗程的R-CHOP治疗（利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松龙）并实现了完全缓解。患者随后接受了包括利妥昔单抗在内的大剂量化疗巩固治疗，随后进行了自体外周血干细胞移植。在整个化疗过程中没有出现诸如肺栓塞、致命性心律失常或急性心力衰竭等并发症。我们的经验表明，这种治疗方法安全有效，可以改善高危PCL的治疗效果。
